Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Corbus Pharmaceuticals Holdings, Inc.

Get SEC filing alerts via email and in your feed for Corbus Pharmaceuticals Holdings, Inc.

CRBP

Corbus Pharmaceuticals Holdings, Inc.

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a biotech company focused on developing therapies for oncology and obesity. Its pipeline includes antibody-drug conjugates targeting solid tumors, TGF-beta pathway inhibitors, and peripheral CB1 receptor antagonists. The company leverages proprietary technologies, licensing agreements, and strategic clinical trials to bring innovative treatments to cancer and metabolic disease markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Corbus Pharmaceuticals Holdings, Inc.

1
1
Corbus Pharmaceuticals Holdings, Inc. Corbus Pharmaceuticals Reports $22.97 Million Net Loss in Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Corbus Pharmaceuticals Holdings, Inc. Corbus Pharmaceuticals Reports $78.5 Million Net Loss and Advances Clinical Pipeline in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Corbus Pharmaceuticals Holdings, Inc. Corbus Pharmaceuticals Reports $23.3 Million Net Loss in Q3 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Corbus Pharmaceuticals Holdings, Inc. Corbus Pharmaceuticals Reports $17.7 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Corbus Pharmaceuticals Holdings, Inc. Corbus Pharmaceuticals Reports $16.98 Million Net Loss in Q1 2025, Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Corbus Pharmaceuticals Holdings, Inc. Corbus Pharmaceuticals Reports $40.2 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Corbus Pharmaceuticals Holdings, Inc. Corbus Pharmaceuticals Reports Improved Financial Position, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments